NKCC1 specific antagonist bumetanide was able to alleviate neuropathic pain (increased withdrawal latency time) after SCI (Cramer et al., 2008; Ahmed et al., 2014) and inhibit brain edema and neuronal death after traumatic brain injuries (Lu et al., 2008; Hui et al., 2016). Here, SLC12A2 is linked to brain injury.